BioAtla, Inc.

NASDAQ:BCAB

0.5 (USD) • At close February 5, 2025
Bedrijfsnaam BioAtla, Inc.
Symbool BCAB
Munteenheid USD
Prijs 0.496
Beurswaarde 28,803,461
Dividendpercentage 0%
52-weken bereik 0.425 - 4.02
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jay M. Short Ph.D.
Website https://www.bioatla.com

An error occurred while fetching data.

Over BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It

Vergelijkbare Aandelen

Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc.

ETON

18.25 USD

Akumin Inc. logo

Akumin Inc.

AKU

0.289 USD

Vigil Neuroscience, Inc. logo

Vigil Neuroscience, Inc.

VIGL

2.73 USD

Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd.

WVE

12.24 USD

SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc.

SABS

2.18 USD

Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc.

ASMB

14.21 USD

Lipocine Inc. logo

Lipocine Inc.

LPCN

4.43 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)